Loading
Calcium-HMB Plus Vitamin D3 / Obesity / Sarcopenia · Phase 2 Trial
ClinicalTrials.gov · August 12, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 2 trial registration for a randomized, placebo-controlled study examining whether calcium-HMB plus vitamin D3 preserves muscle mass in older adults with type 2 diabetes starting semaglutide. No results are posted in this registry record; the study has not yet begun recruitment. The design is methodologically sound but the trial is early-phase and results are not yet available.
Phase 2, Interventional, Randomized, Parallel, Quadruple masking, Prevention purpose. Type 2 Diabetes Mellitus (T2DM), Sarcopenia, Obesity, Muscle Loss, Older Adults; age from 65 Years; to 85 Years. Intervention: Calcium-HMB Plus Vitamin D3. Compared with: Matching Placebo — Placebo Comparator. n = 90. 1 site: United States.
This is a Phase 2 trial registration for a randomized, placebo-controlled study examining whether calcium-HMB plus vitamin D3 preserves muscle mass in older adults with type 2 diabetes starting semaglutide. No results are posted in this registry record; the study has not yet begun recruitment. The design is methodologically sound but the trial is early-phase and results are not yet available.
This is a registry record with no posted results; no outcome data, effect sizes, or safety findings are reported.
This trial is in early recruitment phase and has not produced results. Clinicians should monitor for outcomes once the study completes; the combination approach may inform future guidance on mitigating muscle loss during GLP-1 receptor agonist therapy, but evidence is not yet available.
This is a Phase 2 interventional trial registration with no results posted; the study is not yet recruiting and represents early-phase evaluation of a dietary supplement intervention in a specific population.
As stated by the source record.
Quoted from the source exactly as published.
This trial is in early recruitment phase and has not produced results. Clinicians should monitor for outcomes once the study completes; the combination approach may inform future guidance on mitigating muscle loss during GLP-1 receptor agonist therapy, but evidence is not yet available.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07760948). This is a study registration, not published results. Lead sponsor: Vanderbilt University Medical Center. Recruitment status: NOT_YET_RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 90 participants (ESTIMATED). Conditions: Type 2 Diabetes Mellitus (T2DM), Sarcopenia, Obesity, Muscle Loss, Older Adults. Interventions: DIETARY_SUPPLEMENT: Calcium-HMB Plus Vitamin D3; OTHER: Matching placebo. Primary outcome measures: Change in Appendicular Lean Mass , Baseline to month 6. Brief summary: This randomized, double-blind, placebo-controlled trial will evaluate whether daily calcium beta-hydroxy-beta-methylbutyrate (calcium-HMB) plus vitamin D3 preserves muscle mass, physical function, and resting metabolism in adults aged 65 to 85 years with type 2 diabetes who are newly starting semaglutide as part of usual clinical care. Participants will receive calcium-HMB plus vitamin D3 or matching placebo for approximately 6 months. The primary outcome is change in appendicular lean mass measured by dual-energy X-ray absorptiometry from baseline to month 6. Secondary assessments include body composition, muscle strength, physical performance, gait, physical activity, resting metabolic rate, metabolic measures, and whole-body quantitative computed tomography. An optional mechanistic substudy of up to 36 participants will include D3-creatine dilution, nonradioactive stable isotope infusions, repeated blood sampling, a standardized meal, breath sampling, and vastus lateralis muscle biopsies at baseline and month 6.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.